Clinical trials show weight loss between 15% to 21% for GLP-1s, but this study suggests that weight loss in the real world is ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Novo Nordisk A/S’s latest experimental obesity drug helped patients lose as much as 24.3% of their weight in a small study, ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...